Gan & Lee Pharmaceuticals Co Ltd (603087)

Currency in CNY
68.91
-0.23(-0.33%)
Closed·
603087 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
68.7870.55
52 wk Range
51.5182.25
Key Statistics
Bid/Ask
68.90 / 68.92
Prev. Close
68.91
Open
69.51
Day's Range
68.78-70.55
52 wk Range
51.51-82.25
Volume
6.64M
Average Volume (3m)
12.06M
1-Year Change
-5.2262%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
603087 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
83.00
Upside
+20.45%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 83.00
(+20.45% Upside)

Earnings

Latest Release
Aug 26, 2026
EPS / Forecast
0.69 / 0.77
Revenue / Forecast
1.35B / 1.31B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.94%
Dividend Yield
1.45%
Industry Median 1.77%
Annualized payout
1.00
Paid annually
5-Years Growth
+20.11%
Growth Streak

603087 Income Statement

Compare 603087 to Peers and Sector

Metrics to compare
603087
Peers
Sector
Relationship
P/E Ratio
35.7x35.1x−0.4x
PEG Ratio
1.411.430.00
Price/Book
3.5x2.6x2.6x
Price / LTM Sales
9.7x5.5x3.0x
Upside (Analyst Target)
20.4%40.4%54.5%
Fair Value Upside
Unlock21.0%7.0%Unlock

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People’s Republic of China.

Employees
5309
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
61.59M10.35%4.25B
Other Institutional Investors
34.81M5.85%2.40B
Public Companies & Retail Investors
498.80M83.80%34.39B
Total
595.2M100.00%41.04B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Beijing Xute Hongda Technology Co., Ltd.5.39%32,073,7342,211,484
Minghua Innovation Technology Investment (Hong Kong) Co., Ltd.1.02%6,076,162418,951

People Also Watch

27.27
600580
+0.66%
49.29
603009
+4.05%
7.36
002658
+0.27%
35.95
603039
+1.21%

FAQ

What Is the Gan Lee Pharmaceuticals (603087) Stock Price Today?

The Gan Lee Pharmaceuticals stock price today is 68.91 CNY.

What Stock Exchange Does Gan Lee Pharmaceuticals Trade On?

Gan Lee Pharmaceuticals is listed and trades on the Shanghai Stock Exchange.

What Is the Stock Symbol for Gan Lee Pharmaceuticals?

The stock symbol for Gan Lee Pharmaceuticals is "603087."

Does Gan Lee Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?

The Gan Lee Pharmaceuticals dividend yield is 1.45%.

What Is the Gan Lee Pharmaceuticals Market Cap?

As of today, Gan Lee Pharmaceuticals market cap is 41.02B CNY.

What Is Gan Lee Pharmaceuticals's Earnings Per Share (TTM)?

The Gan Lee Pharmaceuticals EPS (TTM) is 1.94.

When Is the Next Gan Lee Pharmaceuticals Earnings Date?

Gan Lee Pharmaceuticals will release its next earnings report on Oct 22, 2026.

From a Technical Analysis Perspective, Is 603087 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Gan Lee Pharmaceuticals Stock Split?

Gan Lee Pharmaceuticals has split 1 times.

How Many Employees Does Gan Lee Pharmaceuticals Have?

Gan Lee Pharmaceuticals has 5309 employees.

What is the current trading status of Gan Lee Pharmaceuticals (603087)?

As of Sep 19, 2026, Gan Lee Pharmaceuticals (603087) is trading at a price of 68.91 CNY, with a previous close of 68.91 CNY. The stock has fluctuated within a day range of 68.78 CNY to 70.55 CNY, while its 52-week range spans from 51.51 CNY to 82.25 CNY.

What Is Gan Lee Pharmaceuticals (603087) Price Target According to Analysts?

The average 12-month price target for Gan Lee Pharmaceuticals is 83.00 CNY, with a high estimate of 89 CNY and a low estimate of 77 CNY. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +20.45% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.